Search

everythinglearnresearchcommunity

for

Search:↓

Tyrosine kinase inhibitors for endocrine tumors often cause skin issues, requiring early management and treatment adjustments.

JAK inhibitors effectively treat inflammatory skin diseases by targeting specific cytokine signals.

Baricitinib is effective and safe for treating severe alopecia areata.

Oral tacrolimus may be a potential treatment for hair loss that doesn't respond to corticosteroids.

Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.

JAK inhibitors show promise for treating hair loss in alopecia areata but need more clinical trials to confirm safety and effectiveness.

Blocking mTORC1 reduces skin tumor growth in mice.

Baricitinib is effective and safe for treating severe alopecia areata.

Sintilimab treatment caused hair loss but led to complete tumor remission.

Baricitinib may effectively treat nail changes in alopecia areata.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

Using tazarotene with GliSODin improves facial skin more than tazarotene alone.

Janus kinase inhibitors show promise in treating autoimmune skin diseases.

Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.

Combining baricitinib with low-dose corticosteroids significantly improved severe hair loss in eight patients.

Janus kinase inhibitors are effective and safe for treating Alopecia Areata.

Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.

Upadacitinib effectively treated severe hair loss in a child.

CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.

Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.

JAK inhibitors show promise in treating difficult skin diseases.

Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.

Tacrolimus can cause hair loss in kidney transplant patients.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

Baricitinib is effective and safe for treating severe alopecia areata.

Nilotinib can cause keratosis pilaris, a skin condition.

Trametinib can cause skin issues, but they can often be managed without stopping the drug.

Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.

Baricitinib improves alopecia areata and may help psoriasis but might not be ideal for psoriatic arthritis.

Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.